The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.
Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.
Study Type
OBSERVATIONAL
Enrollment
153
Observation only
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
To determine if DASL subclassification can identify a group of patients with advanced melanoma who are significantly more likely to respond to high dose IL-2 based on therapy than the historical 16% response rate in an unselected patient population
Time frame: 2 years
To validate the usefulness of serum fibronectin and VEGF levels as negative predictors of response
Time frame: 2 years
To explore the predictive value of several genetic polymorphisms associated with immune function
Time frame: 2 years
To explore the predictive value of BRAF^V600E mutational status as a predictor of response and benefit to high dose IL-2
Time frame: 2 years
To explore the relationship of serum fibronectin and VEGF levels with the molecular signature of immune responsiveness in patients with advanced melanoma receiving high-dose IL-2 in order to identify specific cohorts with dramatic differences in response
Time frame: 2 years
To identify new proteins or patterns of gene expression that might be associated with high-dose IL-2 responsiveness in order to further narrow the application of IL-2 therapy to those who will benefit the most
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.